Key is sufficient cells, which as you point out, patient results indicate this is so. Now does a new reactor/process optimization yield many times more cells or satisfy more FDA safety concerns or Both?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.